FIGURE 3.

In vitro effect of montelukast on microvesicle (MV) release induced by COVID-19 plasma. Whole blood (WB) from healthy subjects (HS; n = 3), pre-incubated with montelukast (1 µM) as indicated, was plasma-depleted and reconstituted with the COVID-19 plasma pool (dark gray bars) or autologous plasma (light gray bars). The number of TF^pos (A) and platelet-derived TF^pos-MVs (B) was measured by flow cytometry. Data are reported as mean ± SD. **p < 0.01; ***p < 0.001 (TF, tissue factor; plt, platelets).